Clinical Trial

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 8, 2025 (before its estimated May 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
Trial Details
NCT Number NCT07054034
Lead Sponsor Shanghai Mabgeek Biotech.Co.Ltd
Conditions Bronchial Asthma
Enrollment 160 participants
Start Date 2025-05-11
Primary Completion 2026-05-26 (estimated)
Study Completion 2027-05-26 (estimated)
Updated on ClinicalTrials.gov 2025-07-08